Stem cells are receiving a lot of attention for their roles in immunomodulation, inflammation control, and regeneration, and several companies and research institutes are promoting the commercialization of stem cell therapeutics. However, there are currently limitations in the development of stem cell therapies, including their weak efficacy and heterogenic characteristics. Continued exploration is needed to address these challenges and improve therapeutic efficacy.

​

To standardize the therapeutic capacity of stem cell therapies, CELLnLIFE Inc. has developed the “Cell-Matrix Suspension technique” and "S-I-S culture platform," which can minimize the genetic heterogeneity of stem cells and maximize functional gene expression to allow optimal stem cell treatment with excellent functionality and homogeneity.